Korean J Med.
2006 Feb;70(2):183-189.
Paclitaxel for elderly patients with advanced NSCLC
- Affiliations
-
- 1Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. sunghwa@cu.ac.kr
- 2Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
- 3Department of Internal Medicine, Dongguk University College of Medicine, Daegu, Korea.
- 4Department of Internal Medicine, Yeungnam University Callege of Medicine, Daegu, Korea.
Abstract
-
BACKGROUND: Combination chemotherapy including platinum is based on treatment of advanced non-small cell lung cancer (NSCLC). But combination chemotherapy is not tolerable in elderly patients. Paclitaxel is one of the most active single chemotherapeutic agent in advanced NSCLC. We evaluated the efficacy and safety of single paclitaxel chemotherapy in elderly with advanced NSCLC.
METHODS
From September 2002 to May 2004, a total 24 patients aged 70 years and older with advanced NSCLC were enrolled in this study. Treatment was consisted with paclitaxel 135 mg/m2 intravenously for 3hrs on day 1. Chemotherapy repeated every three weeks until disease progression or severe toxicity developed.
RESULTS
Of the 24 patents, only 18 patient can be evaluated and 4 partial remission, 11 stable diseases and 3 progressive diseases were observed. Based on an intent-to-treatment analysis, The overall response rate was 17%. The estimated median survival and median time to progression were 44 weeks and 18 weeks, respectively. The major toxicity were grade 3 or 4 neutropenia (6%). Other toxicity were myalgia, neuropathy, nausea and oral mucositis, but all of them were usually mild (grade 1, 2) and recovered spontaneously. There were no treatment- related deaths.
CONCLUSIONS
This single low dose paclitaxel chemotherapy is highly tolarable with activity comparable to that of conventional dose regimens especially in elderly advanced non-small cell lung cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer
- Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer
- Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer
- Efficacy and Safety of Weekly Low Dose Paclitaxel and Cisplatin as First Line Therapy in Advanced NSCLC of Elderly Patients
- Efficacy of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
